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Treating Hypertrophic
Cardiomyopathy: Two Views
I am writing in response to the published views in JACC regarding
treatment of hypertrophic cardiomyopathy (1). I am the president
of the Hypertrophic Cardiomyopathy Association (HCMA), a
nonprofit organization providing information, advocacy, and sup-
port to patients with this often misunderstood genetic cardiac
disease, and to their families and the medical community. As such,
I have the responsibility to speak on behalf of the over 2,500 HCM
families represented by the HCMA.
The case for surgical septal myectomy presented by Maron et al.
defends and promotes a time-honored treatment strategy with a
balanced, well-referenced discussion, which is consistent with the
recent 2003 American College of Cardiology/European Society of
Cardiology (ACC/ESC) expert consensus panel on the manage-
ment of hypertrophic cardiomyopathy (2). That document pro-
motes surgical myectomy as the primary “gold standard” treatment
for patients with severe heart failure and outflow obstruction
refractory to medical treatment.
The “counterpoint” authored by Drs. Otto Hess and Ulrich
Sigwart (3) was, in contrast, brief and incomplete. Specifically, the
researchers chose to omit the surgical option from their HCM
treatment algorithm. This arbitrary exclusion of surgical myectomy
is contraproductive to providing clinicians and HCM patients with
all the necessary information to understand the treatment options
in this complex disease. The researchers have, therefore, omitted a
treatment strategy from their Figure 1 (pg. 2055) (i.e., septal
myectomy), which has, in fact, provided symptomatic benefits and
enhanced longevity to thousands of HCM patients worldwide for
over 45 years.
It is the role of the HCMA to provide information to our
patients and families, which is accurate and consistent with the
entire body of literature on HCM. Patients have a right to know
all about treatment options available; therefore, it is a disservice to
the patient population for Drs. Hess and Sigwart to arbitrarily
withdraw the “gold standard” treatment of surgical septal myec-
tomy from severely symptomatic obstructive HCM. These com-
ments are presented in the best interests of the HCM patient
population.
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REPLY
We agree completely with Ms. Salberg’s views regarding the
recently published point-counterpoint comparing surgical septal
myectomy and alcohol septal ablation in the management of
obstructive hypertrophic cardiomyopathy (HCM) (1,2). Ms. Sal-
berg asserts that Drs. Hess and Sigwart have been unfair and
misleading by arbitrarily expunging surgery from their HCM
treatment algorithm. Surely, a debate on this important contro-
versy is both warranted and timely, but it is incumbent on all
clinicians to approach the problem with measured judgment and
prudence—for there is much at stake. The central issue is simply
the optimal therapy for the individual patient with obstructive
HCM.
We believe that we have met this threshold honorably in
presenting the case for surgery (1). Conversely, we share Ms.
Salberg’s substantial reservations regarding the brief counterpoint
(2) in which Drs. Hess and Sigwart chose to literally obliterate
surgery from consideration as a treatment option, as clearly evident
in their prominent Figure 1. In the recent American College of
Cardiology/European Society of Cardiology (ACC/ESC) expert
consensus panel recommendations for HCM (3), septal myectomy
is stipulated as the primary and “gold standard” treatment option
for HCM patients with outflow obstruction and severe drug-
refractory symptoms.
Publication of a point-counterpoint on the management of
obstructive HCM was intended to be a fair presentation of
divergent views—that is, pro and con, with one side presenting the
case for surgery and the other supporting ablation, each contrasting
their treatment of choice with the alternative strategy. However,
the decision of Drs. Hess and Sigwart to intentionally leave the
readership with a distinct impression that surgery is now obsolete
is not only intellectually questionable but also very misleading to
the HCM patient population and those practicing cardiologists
charged with the role of gatekeeper in referring HCM patients for
major interventions—such as surgery or ablation. This is particu-
larly relevant given that myectomy is now associated with lower
mortality (and morbidity) than alcohol ablation (1,3,4), and the
recognition that arrhythmic sudden death can be a not uncommon
consequence of ablation (4,5).
It is our absolute obligation to provide both physicians and
patients with complete information regarding all the standard
therapeutic options for drug-refractory severe obstructive HCM,
and to avoid arbitrarily deciding for patients what they should (or
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should not) know, based on personal and unsubstantiated physi-
cian biases.
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REPLY
We do appreciate Ms. Salberg’s concern regarding the best treatment
for patients with hypertrophic obstructive cardiomyopathy. As the
representative of the Hypertrophic Cardiomyopathy Association, Ms.
Salberg must keep a close eye on what should be recommended to
those numerous sufferers from this inherited disease.
Ms. Salberg states that the “counterpoint” we offered in the
Journal of the American College of Cardiology is brief and incomplete
(1). The first statement is correct as it was purposely reduced to the
minimum in order to make it more readable. The second statement
(incomplete) is debatable.
The statement that the investigators have “omitted a treatment
strategy from their Figure 1 (pg. 2055) (i.e., septal myectomy),
which has, in fact, provided symptomatic benefits and enhanced
longevity to thousands of HCM patients worldwide for over 45
years” is, of course, part of the strategy behind the “counterpoint.”
We were asked to make the point for the nonsurgical option.
We do believe that alcohol ablation should be the first treatment
of choice for patients with hypertrophic obstructive cardiomyop-
athy who are not well on medical treatment. As Ms. Salberg
correctly states, the surgical option has been used for 45 years,
although much less over the last 10 years when alcohol ablation
became available. According to the published literature, approxi-
mately 3,000 patients have been treated surgically over those
45 years. In contrast, more than 4,000 patients have been con-
signed to the much less invasive strategy of alcohol ablation, which,
as most investigators agree, provides similar symptomatic relief. As
no randomized trial to compare both treatment options has ever
been conducted, it is difficult to justify the significantly higher
morbidity and probably also mortality of the surgical technique as
a first option.
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